Injections of platelet‐rich plasma prepared by automatic blood cell separator combined with topical 5% minoxidil in the treatment of male androgenetic alopecia
Skin Research and Technology · 2023
DOI: 10.1111/srt.13315 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Skin Research and Technology, 2023. Verfasst von Wei Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Provincial Hospital Affiliated to Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Minoxidil, Platelet-Rich Plasma. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Platelet‐rich plasma (PRP) has been increasingly accepted as a potential therapy in the treatment of androgenetic alopecia (AGA), However, there remains a dearth of data on the effectiveness of PRP prepared by automatic blood cell separator with a combination of topical minoxidil for the treatment of AGA.
Objective
To evaluate the efficacy and safety of PRP prepared by automatic blood cell separator combined with topical 5% minoxidil therapy in male AGA.
Methods
Thirty male patients with mild/moderate AGA were enrolled in a randomized double‐blind controlled study. Patients were randomly divided into two treatment arms: (group A) PRP prepared by automatic blood cell separator combined with topical 5% minoxidil group; (group B) PRP prepared by automatic blood cell separator combined with a topical placebo group. Trichoscopic assessments regarding hair density/quantity and mean hair diameter were performed at baseline and follow‐up. Clinical efficacy of global photography and patient satisfaction were conducted to verify the therapeutic efficacy of the treatment, and the occurrence of adverse reactions was recorded.
Results
We detected a significant increase in all patients in hair density and quantity after PRP treatment ( p < 0.05), and there was no significant difference in mean hair diameter. Although hair density/quantity was more pronounced in group A than in group B, the difference between groups was not statistically significant ( p > 0.05). In terms of clinical efficacy and patient satisfaction, group A was superior to group B, and no serious adverse reactions occurred.
Conclusion
We hereby conclude that the injections of PRP prepared by an automated method are effective and safe in the treatment of mild‐to‐moderate male AGA patients, and its combination with topical 5% minoxidil therapy was superior to PRP monotherapy with better clinical efficacy and higher patient satisfaction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Provincial Hospital Affiliated to Anhui Medical University, Hefei, China.
- Department of Dermatology, The First Affiliated Hospital of the University of Science and Technology of China, Hefei, China.
- Department of Transfusion, The First Affiliated Hospital of the University of Science and Technology of China, Hefei, China.
Zitieren
APA
Wei, W., Zhang, Y., Long, B., Zhang, Y., Zhang, C., & Zhang, S. (2023). Injections of platelet‐rich plasma prepared by automatic blood cell separator combined with topical 5% minoxidil in the treatment of male androgenetic alopecia. Skin Research and Technology. https://doi.org/10.1111/srt.13315
Vancouver
Wei W, Zhang Y, Long B, Zhang Y, Zhang C, Zhang S. Injections of platelet‐rich plasma prepared by automatic blood cell separator combined with topical 5% minoxidil in the treatment of male androgenetic alopecia. Skin Research and Technology. 2023. doi:10.1111/srt.13315
BibTeX
@article{Wei2023,
author = {Wei, Wei and Zhang, Yuanjing and Long, Binman and Zhang, Yuanyuan and Zhang, Chi and Zhang, Siping},
title = {Injections of platelet‐rich plasma prepared by automatic blood cell separator combined with topical 5% minoxidil in the treatment of male androgenetic alopecia},
journal = {Skin Research and Technology},
year = {2023},
doi = {10.1111/srt.13315}
}
EUVIMED